Israeli forces kill 44 people waiting for aid in Gaza, witnesses say
The new food distribution sites run by an American contractor, with US and Israeli government support, have been plagued by scenes of violence and chaos since opening last month.
Palestinian witnesses and health officials say Israeli forces have repeatedly opened fire on crowds heading to the sites for desperately needed food, killing hundreds in recent weeks. The military says it has fired warning shots at people it said approached its forces in a suspicious manner while going to the sites.
In central Gaza, three witnesses told the Associated Press that Israeli forces opened fire as people advanced east towards aid trucks south of Wadi Gaza.
'It was a massacre,' said Ahmed Halawa. He said tanks and drones fired at people 'even as we were fleeing'. He added: 'Many people were either martyred or wounded.'
Hossam Abu Shahada said drones were flying over the area, watching the crowds, then there was gunfire from tanks and drones as people were moving eastwards. He described a 'chaotic and bloody' scene as people tried to escape.
He said he saw at least three people lying motionless and many others wounded.
Israel's military said it was reviewing the incident, which took place near the Netzarim corridor, a road that separates northern and southern Gaza.
The Awda hospital in the urban Nuseirat refugee camp, which received the victims, confirmed 25 deaths and said 146 others were wounded. It said 62 were in a critical condition and transferred to other hospitals.
In the central town of Deir al-Balah, the Al-Aqsa Martyrs hospital said it received the bodies of six people from the same incident.
In the souther-nmost city of Rafah, witnesses said Israeli troops opened fire as crowds tried to reach another food distribution site run by the Gaza Humanitarian Foundation (GHF).
At least 19 were killed and 50 others wounded, according to Nasser hospital and Gaza's Health Ministry.
Two witnesses said Israeli troops started firing as thousands of Palestinians massed at the Shakoush area, several hundred yards from the distribution site.
Salem Ismail was in the crowd and was shot in a leg. He said he saw forces firing towards the crowd who were moving north towards the site.
Ayman Abu Joda said he saw heavy gunfire from Israeli tanks and that many people were shot. He said he helped evacuate three wounded people, one hit in the chest and two in the legs.
'It was the same tragedy every day: We seek food and the occupation opens fire and kills many,' he said.
The casualty toll was confirmed to the Associated Press by Zaher al-Waheidi, head of the Health Ministry's records department.
The GHF said on social media its hub there opened Tuesday at 10am and closed after finishing food distribution. It called on people not to head to the hub.
Israel wants the GHF to replace a system co-ordinated by the United Nations and international aid groups. Along with the United States, it accuses Hamas of stealing aid, without offering evidence. The UN denies there is systematic diversion of aid.
The GHF sites are in Israeli military zones where independent media have no access.
Meanwhile, Gaza's Health Ministry said Israel's 21-month military operation in Gaza has killed 56,077 people.
The war was sparked by Hamas's surprise attack on southern Israel on October 7 2023, that killed around 1,200 people, mostly civilians, and took 251 others hostage. Many have been released by ceasefire or other agreements.
The death toll is by far the highest in any round of Israeli-Palestinian fighting.
The ministry said the dead include 5,759 who have been killed since Israel resumed fighting on March 18, shattering a two-month ceasefire.
The ministry does not distinguish between civilians and combatants but says more than half of the dead were women and children.
Israel says it only targets militants and blames civilian deaths on Hamas, which operates in heavily populated areas. Israel says more than 20,000 Hamas militants have been killed, though it has provided no evidence to support that claim.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Spectator
3 hours ago
- Spectator
Britain owes America for its ‘free' healthcare
'A friend of mine who's slightly overweight, to put it mildly, went to a drug store in London,' Donald Trump said aboard Air Force One. Earlier he had told reporters: 'He was able to get one of the fat shots. 'I just paid $88 and in New York I paid $1,300. What the hell is going on? It's the same box, made in the same plant, by the same company.'' You can see why the dealmaker-in-chief was irked. And when Trump is irked, someone usually pays the price. In May, the President signed an executive order for 'most-favoured-nation prescription drug pricing for American patients'. It was a warning to drug companies, as well as other countries, that Americans were tired of paying nearly three times more for the same medicines as patients abroad. The US is home to less than 5 per cent of the world's population and yet American consumers account for almost three-quarters of global pharmaceutical profits, because manufacturers heavily discount their drugs overseas and make up the difference by inflating prices in the States. As the President puts it, 'freeloading' foreign customers 'get a free ride'. He's not wrong. But while Trump may get his wish in stopping overseas health systems from getting cheaper deals, it's not obvious that profit–making companies will cut their prices in America. The more likely response is that they'll raise them everywhere else. Eli Lilly, the American pharmaceutical giant behind the weight-loss jab Mounjaro, has announced that from September the recommended retail price of its strongest monthly dose in Britain will leap from £122 to £330 – inflation of more than 170 per cent. The company knows the NHS won't actually pay that much: it has already negotiated substantial discounts for the doses it prescribes. But by hiking the list price on the highest dose (which relatively few patients use), while cutting the private deals on lower doses, Lilly can appease Washington and protect its market at the same time. For now, anyway. But demand is picking up. In Britain, around 1.5 million people are already on weight-loss drugs, with 90 per cent paying out of pocket. Most take Mounjaro, while a smaller number are on Wegovy, the sister drug to Ozempic. Novo Nordisk, the Danish manufacturer of Wegovy, has agreed to keep its UK price low for the time being. But costs will eventually be driven up for Wegovy users too if Mounjaro users, faced with a much bigger bill, convert to Wegovy en masse, squeezing supply. Fat loss clinics are already seeing a 500 to 600 per cent increase in Brits switching to Wegovy, which – come September – will cost half the price of Mounjaro. Trump's war on drug pricing will affect other areas of British medicine too. Weight-loss jabs have become the symbol of American pharma – and its many excesses – but they are by no means the only miracle drug we get for cheap. Take Casgevy, a US-made gene therapy that can treat the blood conditions beta thalassemia and sickle cell disease. One dose costs more than £1.6 million at list price. Thanks to its clout as the country's single dominant buyer, the NHS has secured a confidential – though significant – discount. Casgevy's eye-watering price is easy to justify: therapies at the frontier of medicine cost billions to develop. British politicians love to remind us that the UK is a world leader in life sciences, and in many ways that's true, but it's the US that is funding nearly half of all global life-sciences research and development. Trump, in typical fashion, wants the credit – or at least cheaper price tags. But drug makers won't cut their profits; they'll shrink everyone else's discounts. The NHS's bargaining power may shield patients for a time, but price rises are coming. UK officials know it, too. Even before the latest hikes on the fat jabs, government papers released alongside the US-UK trade talks in May noted that the NHS would look at the concerns of the President. No prime minister or health secretary could openly sign up to higher drug costs borne by the NHS, but they knew Trump had not finished going after what he considers to be unfair trade practice. The uncomfortable truth for the British is that as much as we mock US healthcare as extortionate and venerate our NHS as sacred, we live off America's excess. The American healthcare system is Britain's greatest scapegoat: it's absurdly expensive, highly inefficient and still doesn't manage to provide universal coverage. Indeed, it's the only healthcare system in the developed world that can distract from just how poor our own is: a 'National Health Service' that falls short of practically every standard and target set for it. The NHS survives only because we ignore its outcomes. Measure after measure shows that plenty of people are being failed by an expensive, yet decaying system. Britain spends around £36 billion a year on pharmaceuticals, £19 billion of that coming from the NHS. Medicines are already the health service's second-biggest expense after staff. But that number would be a lot higher without America. Britain may be world-class in medical research, but we spend just 0.3 per cent of GDP on drug research and development, compared with America's 0.8 per cent. American money makes Britain's drug research possible. And for years, until drugs lose their patent, Americans pay exorbitant costs which subsidise the NHS's bargain prices. This model which so annoys Trump perhaps helps explain why the NHS continues to enjoy such widespread public support, despite its many failures. We'll tolerate months-long waiting lists, worse survival chances and outdated facilities if we have cheap or 'free' access to life-changing medicines. But will we put up with the broken system if we have to start paying a fair whack for drugs, either directly at the pharmacy counter or indirectly through the increased taxation that would be needed to fund them? The government won't give up our bargain pricing without a fight. Quietly, and at significant political cost, health officials will roll out a new strategy. We're never going to pay American prices for drugs – the 'free at the point of use' funding model simply could not afford it. Instead, we'll try to make our research environment so attractive to manufacturers that they'll reward us by maintaining drug discounts. That's the real motivation behind Wes Streeting's planned reforms for the NHS, which are championed by his supporters as a way to improve the patient experience and attacked by his critics as a covert means of privatising the health service. Take the single patient record, which NHS England says will give 'every part of the NHS a full picture of the patient'. Perhaps – but it will also make it far easier to identify people for clinical trials and medical research. Look at the partnership between the Wellcome Trust and the government to create a £600 million health data research service. The stated aim is to 'simplify access to health data and speed up research'. But it also makes Britain an attractive place for pharmaceutical companies. The offer is simple: we'll make it as easy and welcoming as possible for you to do your research here, you've just got to keep paying for it. This is the part British politicians never want to say out loud, especially when it comes to healthcare: someone, somewhere, is always paying for it. Drugs aren't 'cheap'. The NHS isn't 'free'. There are always trade-offs: either higher prices, longer wait times, or uncomfortable deals and data swaps with Big Medicine. No matter how you spin it, Britain's 'free ride' is coming to an end.
Economist
7 hours ago
- Economist
RFK Jr's attack on mRNA technology endangers the world
DURING THE covid-19 pandemic new vaccines were rolled out with unprecedented speed. The fastest to arrive were jabs built from molecules of messenger RNA (mRNA) designed to teach the body how to fight off the disease-causing virus. By late 2021, mRNA vaccines had saved an estimated 7.7m lives globally, including most of the 3m Americans whom the Commonwealth Fund, an American health-care charity, estimates were saved by vaccines before 2023.
Glasgow Times
7 hours ago
- Glasgow Times
Midwife brings claim against trust after ‘Prevent referral over Palestine posts'
Chelsea and Westminster Hospital NHS Foundation Trust made the referral to the Home Office's early intervention counter-terrorism programme, along with one to the Nursing and Midwifery Council regulator, a year after Fatimah Mohamied had resigned from her employment and following a complaint about her online activity from UK Lawyers for Israel (UKLFI), according to law firm Leigh Day. The mother-of-two, who lives in London, alleges the referrals breach her rights under the Equality Act 2010 and constitute post-employment harassment and/or discrimination. She said: 'I have been subjected to a concerted and targeted effort to intimidate, harass and punish me into silence for my Palestinian advocacy and criticism of Zionism. 'I am taking legal action against my former employer to finally seek accountability for a campaign of harassment against me in the midst of a live genocide perpetrated by the Israeli state – I will not accept the attempts to silence me and those like me. 'Healthcare workers in the NHS have the right to critique a colonial political ideology that has upheld an illegal occupation for decades and is responsible for violating universal values of health.' A complaint was lodged on October 8 2023 about Ms Mohamied's social media posts in which she voiced her support for Palestinian people and her opposition to Zionism in the wake of the October 7 attacks in Israel, according to Leigh Day. Her line manager asked her to consider deleting the posts or her account but she refused to do so. Three further complaints were made about the midwife's social media posts and on December 20 2023 the trust received a letter from UKLFI accusing Ms Mohamied of expressing support for Hamas. In early January the following year, the trust's director of maternity told Ms Mohamied that if they received 'more emails or letters of concern' her actions could be considered misconduct. Ms Mohamied, who was employed as a 'cultural safety lead' midwife and who had worked at the trust since June 2019, resigned in March last year. In March of this year, the trust received a second letter from UKLFI which launched further complaints about further social media posts and accused Ms Mohamied of anti-semitism, bullying and harassment and of stirring up racial hatred against Jews and Israelis. Towards the end of the month, the trust referred Ms Mohamied to the Nursing and Midwifery Council and then to the Metropolitan Police under Prevent over her online activity. Both referrals were dismissed, and Leigh Day said in a letter to the trust that the regulator and police each assessed Ms Mohamied's posts 'amounted to lawful expression of her beliefs and did not present cause for concern'. Liana Wood, partner at the law firm, said: 'We say the trust's referrals against Fatimah, made a year after she had stopped working for them, were an entirely disproportionate response to her lawful expressions of belief on her personal blog and social media accounts. 'Fatimah's case, which has parallels with other cases we have seen recently in the NHS, highlights the need for employers to resist pressure from lobby groups in such cases, and to carefully consider any potential infringement on an individual's rights before taking action against them.' The hospital trust has been contacted for comment.
